Background: Vascular surgery patients are at increased risk for late sudden cardiac death. Identification of patients at risk during surgery offers the opportunity for focused therapy. Methods: We monitored 483 vascular surgery patients who had no documented history of arrhythmias to identify perioperative new-onset ventricular tachyarrhythmia (VT) and myocardial ischemia using a continuous electrocardiographic (ECG) device for 72 hours. Cardiac risk factors, left ventricular ejection fraction (LVEF), medical therapy, inflammation status, and perioperative ischemia in relation to arrhythmia were noted in all patients. During follow-up, event-based outcomes analysis was used to describe survival. Results: New-onset perioperative VT was detected in 33 patients (6.8%). A higher percentage of patients experiencing perioperative VT had reduced LVEF preoperatively than those without VT (24% vs 12%; P ‫؍‬ .04). Additionally, fewer patients experiencing VT were receiving statins than those without (70% vs 85%; P ‫؍‬ .02). Patients experiencing VT had a higher incidence of myocardial ischemia (30% vs 18%; P ‫؍‬ .10). Perioperative VT was preceded by ischemia in only 60% of the cases. The overall cohort survival was 83% at 24-month follow-up (interquartile range 
Sudden cardiac death is among the most common causes of death in developed countries. Sudden cardiac death accounts for more deaths each year, and it is estimated that more than 3 million people die yearly from sudden cardiac death worldwide. 1 The incidence of sudden cardiac arrest in the general Dutch population is 9.2 per 10,000 inhabitants. 2 This can be extrapolated to approximately 40 sudden cardiac arrests per day in The Netherlands. 3 In Dutch patients who had undergone 24-hour ambulatory electrocardiography (ECG) monitoring for various indications, 3.7% of the patients experienced sudden death within 2 years after ECG. 4 The majority (80% to 85%) of such sudden cardiac deaths are caused by acute ventricular tachyarrhythmia (VT), which can be triggered by acute coronary events, which may occur in persons without known cardiac disease or in association with structural heart disease. 1, 5 Patients undergoing vascular surgery are at increased risk of cardiac events, such as cardiac arrhythmias and myocardial infarction (MI). 6 The use of perioperative continuous-ECG monitoring to screen for the presence of ischemia and arrhythmia increases the number of patients identified with arrhythmic events and may help to improve management of patients at risk for subsequent cardiac events. 7 The significant influence of an increased incidence and detection of perioperative myocardial ischemia and arrhythmias in vascular surgery patients has been described previously. 8 In this study, we tried to identify vascular surgery patients at risk of developing new-onset perioperative VT, registered with continuous ECG, and late sudden cardiac death.
METHODS
Study population. The prospective study cohort consisted of 483 patients undergoing vascular surgery at the Erasmus Medical Center in Rotterdam, The Netherlands, from December 2004 to October 2009. Patients with a history of cardiac arrhythmias, cardiac pacemaker, and/or implantable cardioverter defibrillator (ICD) were excluded. Procedures that precluded continuous Holter ECG monitoring were excluded. The hospital's ethical committee approved this study.
Preoperative cardiac screening. The relationship between patient characteristics and the risk of adverse cardiac outcome was determined at the outpatient clinic, as previously described by Boersma et al. 9 We determined the cardiac risk score for each patient in our dataset, and one point was assigned to each of the following characteristics: advanced age (Ͼ70 years), history of MI, angina pectoris (AP), congestive heart failure (CHF), stroke (transient ischemic attack, and/or cerebral vascular accident), diabetes mellitus (fasting glucose level Ն7.0 mmol/L, or use of insulin, or oral glucose lowering medication), and renal insufficiency (serum creatinine Ͼ170 umol/L). 9 Based on the number of these risk factors, patients were stratified into low-risk (no risk factors), intermediate-risk (1 or 2 risk  factors) , and high-risk (Ն3 risk factors) categories. 9 Venous blood samples for C-reactive protein (CRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) were routinely performed at the outpatient clinic. A preoperative ECG assessment of the left ventricle ejection fraction (LVEF) was performed in all patients at the outpatient clinic. On admission to the hospital, all patients received beta-blockers.
ECG monitoring. Patients were continuously monitored with a 10-electrode, 12-lead, digital ECG recorder (DR180ϩ Digital Recorder; NorthEast Monitoring Inc, Maynard, Mass) for 72 hours perioperatively, starting 1 day before their surgical procedure and continuing until 2 days after. ECG data were analyzed for ischemia and new-onset VTs (sustained ventricular tachycardia and ventricular fibrillation [VF]). Sustained ventricular tachycardia was characterized by three or more consecutive QRS complexes with a wide QRS complex at a rate of greater than 100 beats per minute (bpm) and duration greater than 30 seconds. 7 VF was defined as chaotic ventricular electrical discharge with marked variability in QRS cycle length, morphology, and amplitude. 7 Episodes of ischemia were defined as reversible ST-segment changes, lasting at least 1 minute and shifting from baseline by more than 0.1 mV (1 mm). The baseline ST-segment level was defined as the average STsegment value during a stable period of at least 20 minutes' duration. The criteria for an ST-depression and ST-elevation were 0.1 mV flat or down-sloping morphology with deviated J-point. 10 Standard postoperative 12-lead ECGs were made on days 3, 7, and 30, and/or at discharge, and whenever clinically indicated.
Cardiac troponin-T measurement. After surgery, cardiac troponin-T (cTnT) levels were routinely measured on postoperative days 1, 3, 7, and 30, and/or before hospital discharge, and/or whenever clinically indicated by chest pain complaints or ECG changes consistent with myocardial ischemia or infarction. The cTnT level was measured using a whole blood rapid test by an electrochemiluminescence immunoassay (TropT version 2; Roche Diagnostics GmbH, Mannheim, Germany). The lower limit of cTnT detection was 0.01 ng/mL and the upper limit of detection was 25 ng/mL, with the limit of quantification set at 0.03 ng/mL. If cTnT release occurred, measurements were repeated every day until the level returned to baseline value.
Outcomes. During follow-up, outpatient visits were scheduled every 3 months after hospital discharge. The study endpoint was sudden cardiac death. Sudden cardiac death was defined as a witnessed natural death attributable to cardiac causes, heralded by abrupt loss of consciousness, within 1 hour of onset of acute symptoms, or an unwitnessed, unexpected death of someone seen in a stable medical condition Ͻ24 hours previously with no evidence of a noncardiac cause. 11, 12 Cardiac death was defined as any death with a cardiac cause, including deaths after a cardiac procedure, cardiac arrest, MI, pulmonary embolus, stroke, or sudden death not ascribed to other causes. 13 The composite of cardiac death, MI, unstable angina, and stroke was considered as cardiac events. Survival status was determined by contacting the municipal civil service registry by use of electronic medical records and contacting the patient's general practitioner.
Data analysis. Continuous data are expressed as mean Ϯ SD compared using the Student's t-test. Continuous data with a skewed distribution are expressed as medians with interquartile ranges (IQRs) and were compared using the Mann-Whitney U test. Categorical data are described as numbers and percentages and analyzed using the 2 test or Fisher's exact test as appropriate. The relationship between new-onset perioperative VT and sudden cardiac death was assessed with multivariate Cox regression analysis. In multivariate analysis, adjustments were made for gender, cardiac risk index (medical history of MI, CHF, stroke, AP, renal dysfunction, diabetes, and age) and type of surgery. In addition, a cumulative 2-year survival curve for vascular surgery patients experiencing VT and without perioperative VT was determined by the Kaplan-Meier method and compared using the log-rank test. Odds ratios and hazard ratios (HRs) are given with 95% confidence intervals (CIs). For all tests, a P value of less than .05 (two-sided) was considered significant. All analyses were performed using SPSS 15.0 statistical software (SPSS Inc, Chicago, Ill). Continuous ECG recordings and the data were analyzed off-line and thus did not influence perioperative treatment management.
RESULTS

Study population.
The baseline clinical characteristics and medication use of the 483 included patients undergoing elective abdominal aortic aneurysm repair (n ϭ 241), peripheral artery bypass surgery (n ϭ 101), and carotid artery surgery (n ϭ 141) are listed in Table I . The mean age at baseline was 68.6 Ϯ 9.5 years, and 76% were men. The preoperative cardiac risk was assessed and showed that 18% had low risk, 57% had intermediate risk, and 25% had high risk.
Risk factors for perioperative cardiac arrhythmias. Patients with new-onset VT were significantly older, as shown in Table I . Twenty-four percent of patients with perioperative VT had an LVEF lower than 40%, as compared to 12% of those without new-onset VT (P ϭ .04). Patients with perioperative VT had elevated NT-proBNP levels (36 vs 21 pg/mL; P ϭ .02). A significantly lower percentage of patients developing perioperative VT were treated with statins (70% vs 85%; P ϭ .02), however, neither their baseline inflammation status (preoperative CRP 6 vs 4 mg/L), nor LDL (46.8 vs 48.6 mg/dL), or HDL (23.4 vs 23.4 mg/dL) differed from patients without perioperative VT. Chronic beta-blocker therapy was used in 88% (388 of 441) of those patients receiving preoperative beta-blocker therapy.
New-onset perioperative ventricular tachyarrhythmia. Continuous ECG monitoring started on average 12.4 Ϯ 7.6 hours before surgery. New-onset perioperative VT occurred in 33 patients (6.8%), and sustained ventricular tachycardia and VF occurred in 6.6% and 0.2%, respectively. The vast majority of patients with cardiac arrhythmias (97%) were asymptomatic. All but 1 patient with new-onset VT returned to sinus rhythm at 30 days postoperatively, confirmed by standard 12-lead ECG. As shown in Table I , significantly more patients undergoing aortic aneurysm repair experienced perioperative VT (open, 30% vs endovascular, 43%), as compared to those undergoing carotid artery operation (carotid endarterectomy, 6% and carotid stenting, 3%) and peripheral artery bypass procedure (open, 18%).
VT and myocardial ischemia during continuous Holter electrocardiogram. Transient myocardial ischemia was detected in 93 patients (19.3%), in 9 patients as ST elevation and 84 patients as ST depression. Patients with new-onset VT had a higher but nonsignificant incidence of myocardial ischemia, compared to patients without VT, during continuous ECG registration (30% vs 18%; P ϭ .10, Table II ). New-onset perioperative VT was preceded by myocardial ischemia in 60% of the cases. Patients developing new-onset VT and myocardial ischemia had significantly higher postoperative heart rates (median heart rate 80 vs 68; P ϭ .04). Perioperative cTnT release occurred in 75 of 483 patients (16%). In patients experiencing perioperative VT, cTnT release occurred nonsignificantly more as compared to those not experiencing VT (24% vs 15%, respectively; P ϭ .15). In addition, cTnT and myocardial ischemia were detected more often in those patients undergoing elective aneurysm repair (P Ͻ .001) as compared to carotid artery surgery and peripheral bypass procedures. Outcomes. A total of 80 patients (17%) died during the follow-up period (median follow-up of 2.0 years; IQR, 1.1-3.1), 56 (70%) were due to cardiac causes. Sudden cardiac death (n ϭ 52) occurred in significantly more patients with perioperative VT compared to those without VT during vascular surgery (21% vs 10%; P ϭ .045, respectively, Table II ). The median onset of perioperative VT to the occurrence of sudden cardiac death was 19 days. As shown in the Kaplan-Meier curve, the detection of perioperative VT was associated with an increased risk of sudden cardiac death (Fig) . In univariate analysis, the development of new-onset perioperative VT was independently associated with a significant 2.4-fold increased risk of long-term sudden cardiac death. After correction for gender, cardiac risk factors, and type of surgery, new-onset perioperative VT was still found to be independently associated with long-term sudden cardiac death and all-cause mortality (HR, 2.57; 95% CI, 1.14-5.79, respectively, and HR, 2.06; 95% CI, 1.02-4.19, respectively, Table III ).
DISCUSSION
The use of perioperative continuous ECG monitoring to screen for the presence of ischemia and arrhythmia helps to identify patients at risk for late sudden cardiac death. More patients with new-onset VT (incidence 6.8%) had a reduced LVEF and fewer patients received statin therapy preoperatively. The present study demonstrates that the identification of new-onset VT in patients undergoing vascular surgery could account for a high proportion of late sudden cardiac death.
Sudden death from cardiac causes accounts for approximately 50% of all deaths from cardiovascular diseases and 20% of all deaths. 2, 14, 15 In the current study population, the incidence of sudden cardiac death was 10.8% (52 of 483). When looking into the patients with perioperative VT, this incidence of sudden cardiac death was higher (21%). The diagnosis of sudden cardiac death is a difficult exercise, and within a clinical trial, it generally relies on source documentation that indicates that death was sudden and unexpected, which was the case in the current study. Because a large proportion of sudden cardiac death victims have no warning symptoms, it would be essential to identify the patients at high risk of long-term sudden death. In a study by Pouleur et al, 16 the specific cause of sudden death from autopsy reports was examined and found that 51.4% of the sudden death cases had no acute specific structural autopsy evidence and presumed arrhythmia. Despite decades of investigation, the ability to stratify the risk for sudden cardiac death is imperfect at best, as evidenced by the fact that, even among patients with no risk factors, sudden death occurs at a rate just less than 1% per year; patients with Ն3 risk factors seem to have event rates that approach 5% per year, whereas even survivors of prior sudden death have a rate of subsequent sudden death of approximately 10% per year. 17 In the latter, mentioned study by Maron et al, 17 the risk factors for sudden death were assessed in 506 patients with hypertrophic cardiomyopathy and implanted with an ICD. Their conclusion was that ICD interventions for life-threatening VTs were frequent and highly effective in restoring normal rhythm and that a single marker of high risk for sudden death may be sufficient to justify consideration for prophylactic defibrillator implantation. 17 In the current study, sudden cardiac death was found more frequently in patients with increased cardiac risk factors (medical history of MI, AP, stroke, CHF, diabetes, renal dysfunction, and age higher than 70 years) eg, patients with a high risk had an HR of 2.82 for sudden cardiac death and could thus be indicated for prophylactic ICD. In the most recently published randomized controlled trial by Steinbeck et al, 18 however, patients with an acute MI had no improved survival after prophylactic ICD placement, compared to those treated medically only. The main difference between Steinbeck's study population and that from the current study is the fact that all Steinbeck's patients had an acute MI before being randomized to an ICD. In previously published studies [19] [20] [21] reporting that the use of ICD reduces mortality in high-risk populations with ischemic disease, patients were recruited more than 1 year after the index MI. Hohnloser et al 22 conducted the DINAMIT (Defibrillator IN acute MI Trial) and concluded that prophylactic ICD therapy did not reduce overall mortality in high-risk patients with a recent MI (enrolled 6 to 40 days after an acute MI), even though it was associated with a reduction in the rate of death due to arrhythmia that was offset by an increase in the rate of death due to nonarrhythmic causes. 22 In the current study population, the majority of patients were treated optimally with medical therapy. However, it is notable that a lower percentage of patients who experienced VT were receiving preoperative statin therapy (70%) compared to those who did not experience arrhythmias (85%), even though baseline CRP levels were not different between these groups. A previous study by Vyas et al 23 concluded that statin use in patients with an ICD were associated with fewer VT/VF episodes and a 28% reduction in risk of a first VT/VF episode. It could be hypothesized that the patients developing perioperative new-onset VT in the current study could benefit from statin use and that some of the patients, especially those with VT before MI, may benefit from an ICD implant to prevent sudden cardiac death. In the end, the choice whether to pursue an ICD comes down to whether the individual patients and their physicians perceive that the risk of sudden death outweighs the risk of device placement. In the current study population, 45 of 52 patients who died due to sudden cardiac death were not identified with perioperative VT. By extending the ECG monitoring period with an implantable monitoring device recording online, the chances of capturing more episodes of new-onset VT increase, especially those presenting outside the 72-hour ECG window, which in turn could enhance detection of those at highest risk of sudden death.
Study limitations. Larger studies will make a better understanding of the triggers for ventricular arrhythmias and better risk stratification algorithms. This study has the major limitation that it is a relatively small cohort, which likely precludes a full characterization of the relationship between perioperative ventricular arrhythmias and sudden cardiac death.
In conclusion, perioperative VT during vascular surgery procedures is suggested to be associated with late sudden cardiac death and decreased survival. Larger studies will need to be conducted to prove this finding. Long-term continuous perioperative ECG is an effective method to identify perioperative VT and may allow improved management of patients undergoing vascular operations. 
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Dr Richard P. Cambria (Boston, Mass). Congratulations, your group has been a leader in the entire area of cardiac risk stratification and events, and it's a pleasure to comment on a paper that reinforces one's personal bias and calls back to the days when Charlie Boucher and Kim Eagle identified a history of ventricular arrhythmias as one of the clinical markers.
My question is: Having identified perioperative VT, was pharmacologic antiarrhythmia therapy instituted in these patients and/or is that your current recommendation? You mentioned in the abstract that you might consider an ICD placement in that circumstance, but how about drug therapy? Dr Tamara A. Winkel. Unfortunately, we analyze our Holter data off-line, so only in the cases of clinical signs of dyspnea or anything that the patient complained of, or with abnormalities on an electrocardiogram, we could see if there was VT and act on these findings with medical therapy. So there was no direct pharmacological implications on these measurements if it was not seen in the clinical setting or on standard ECG.
However, if we did find and measure or detect these in the clinical setting itself, then indeed we did use pharmacological therapies such as beta blockers, in the cases when the patient wasn't receiving it or we changed the doses hereof. Also, the patient received antiplatelet or anticoagulant therapy or statin therapy when necessary.
And while our data now state that there is a non-significant difference of ischemia with the patients of ventricular tachycardia, so we don't have hard data or arguments to imply an ICD, we do hope that by enlarging our study population we could say something more about this ICD implantation in the future. An online monitoring of the continuous electrocardiogram would be better and then we can, indeed, imply therapeutic consequences.
Dr Richard P. Cambria. So if we, as practitioners, identify perioperative VT, what is the appropriate posture? Should antiarrhythmic therapy be instituted? Dr Tamara A. Winkel. Well, with regard to antiarrhythmic therapy, several studies have been done, and the preference goes out to beta blockers and antiplatelet or anticoagulation therapy in cases of ventricular tachycardia. In this study, antiarrhythmic medication was not given as the first antiarrhythmic therapy. Then I would say no. Dr Richard P. Cambria. I hate to pin you down, but 98% of your patients were already on beta blockers.
Dr Tamara A. Winkel. Yes, this is true. Dr Richard P. Cambria. So that would appear to be insufficient.
Dr Tamara A. Winkel. You could adjust or change the doses, make it a higher dose.
Dr Jack L. Cronenwett (Lebanon, NH). I would also congratulate you on presenting what I think is a novel observation about our patients.
My question relates to whether this is a marker for a future earlier death or does it have a causative relationship? I didn't understand from your presentation how you were able to classify sudden cardiac deaths. Were you able to analyze the cause of death in these patients to understand if, in fact, these late deaths that were more frequent were related potentially to a ventricular arrhythmia or is this just a marker for patients, because of their cardiac burden, who are going to die earlier? I think that has important implications for how we might manage them, reply Dr Cambria's questions, when we see them in the hospital.
Dr Tamara A. Winkel. Indeed, it is so that patients with structural heart disease or more cardiac risk factors are more prone to develop these ventricular tachycardia's. That's one side of the problem.
On the other hand, we do believe that it is an independent factor for the eventual development of sudden cardiac death. So we do think that it is an independent marker, but there is also the risk factors causing them to develop ventricular tachycardia. It's the chicken-or-the-egg story, but you can't really say if ventricular tachycardia's are either the chicken or the egg in this story. It's difficult. We have shown that it is an independent factor, but we do believe that there are other factors contributing to its development.
And with regard to your question about sudden cardiac death, we contacted the general practitioners when the patients were discharged. We looked into the survival status with use of the civil service registry data, and contacted the patients via regular visits at the outpatient clinic. So we really looked into that to the best of our abilities, yes.
